657 related articles for article (PubMed ID: 26486166)
1. Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease.
Le NA; Tomassini JE; Tershakovec AM; Neff DR; Wilson PW
J Am Heart Assoc; 2015 Oct; 4(10):e001675. PubMed ID: 26486166
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
Jimenez JG; Rosen JB; Pirags V; Massaad R; Hanson ME; Brudi P; Triscari J
Diabetes Obes Metab; 2013 Jun; 15(6):513-22. PubMed ID: 23279632
[TBL] [Abstract][Full Text] [Related]
3. Effects of Extended-Release Niacin on Quartile Lp-PLA
Lyubarova R; Albers JJ; Marcovina SM; Yao Y; McBride R; Topliceanu A; Anderson T; Fleg JL; Desvigne-Nickens P; Kashyap ML; McGovern ME; Boden WE
J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):534-541. PubMed ID: 31131629
[TBL] [Abstract][Full Text] [Related]
4. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.
Ambegaonkar BM; Tipping D; Polis AB; Tomassini JE; Tershakovec AM
Atherosclerosis; 2014 Dec; 237(2):829-37. PubMed ID: 25463129
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
[TBL] [Abstract][Full Text] [Related]
6. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
[TBL] [Abstract][Full Text] [Related]
7. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Giugliano RP; Cannon CP; Blazing MA; Nicolau JC; Corbalán R; Špinar J; Park JG; White JA; Bohula EA; Braunwald E;
Circulation; 2018 Apr; 137(15):1571-1582. PubMed ID: 29263150
[TBL] [Abstract][Full Text] [Related]
8. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
Constantinides A; de Vries R; van Leeuwen JJ; Gautier T; van Pelt LJ; Tselepis AD; Lagrost L; Dullaart RP
Eur J Intern Med; 2012 Oct; 23(7):633-8. PubMed ID: 22902096
[TBL] [Abstract][Full Text] [Related]
9. Medication Discontinuation in the IMPROVE-IT Trial.
Navar AM; Roe MT; White JA; Cannon CP; Lokhnygina Y; Newby LK; Giugliano RP; Tershakovec AM; Braunwald E; Califf RM; Blazing MA
Circ Cardiovasc Qual Outcomes; 2019 Jan; 12(1):e005041. PubMed ID: 30630361
[TBL] [Abstract][Full Text] [Related]
10. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy.
Lorenzi M; Ambegaonkar B; Baxter CA; Jansen J; Zoratti MJ; Davies G
Clin Res Cardiol; 2019 May; 108(5):487-509. PubMed ID: 30302558
[TBL] [Abstract][Full Text] [Related]
11. Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients.
Ahmed O; Littmann K; Gustafsson U; Pramfalk C; Öörni K; Larsson L; Minniti ME; Sahlin S; Camejo G; Parini P; Eriksson M
J Am Heart Assoc; 2018 Dec; 7(24):e009876. PubMed ID: 30561264
[TBL] [Abstract][Full Text] [Related]
12. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
[TBL] [Abstract][Full Text] [Related]
14. Second-line treatments for dyslipidemia in patients at risk of cardiovascular disease.
Kondo Y; Hamai J; Nezu U; Shigematsu E; Kamiko K; Yamazaki S; Yoshii T; Takahashi M; Takano T; Kawasaki S; Yamada M; Yamakawa T; Terauchi Y
Endocr J; 2014; 61(4):343-51. PubMed ID: 24452015
[TBL] [Abstract][Full Text] [Related]
15. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
Saougos VG; Tambaki AP; Kalogirou M; Kostapanos M; Gazi IF; Wolfert RL; Elisaf M; Tselepis AD
Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2236-43. PubMed ID: 17656665
[TBL] [Abstract][Full Text] [Related]
16. Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects.
Rosen JB; Jimenez JG; Pirags V; Vides H; Massaad R; Hanson ME; Brudi P; Triscari J
Lipids Health Dis; 2013 Jul; 12():103. PubMed ID: 23866306
[TBL] [Abstract][Full Text] [Related]
17. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
Cao X; Ejzykowicz F; Ramey DR; Sajjan S; Ambegaonkar BM; Mavros P; Tunceli K
Clin Ther; 2015 Apr; 37(4):804-15. PubMed ID: 25626487
[TBL] [Abstract][Full Text] [Related]
18. A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease.
Rosen JB; Jimenez JG; Pirags V; Vides H; Hanson ME; Massaad R; McPeters G; Brudi P; Triscari J
Diab Vasc Dis Res; 2013 May; 10(3):277-86. PubMed ID: 23288881
[TBL] [Abstract][Full Text] [Related]
19. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
[TBL] [Abstract][Full Text] [Related]
20. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
